This study is testing two treatments, **Tarcocimab Tedromer** and **Tabirafusp Tedromer**, to see if they work well and are safe for people with a condition called **neovascular (wet) age-related macular degeneration (wAMD)**. This condition affects the eyes and can make it hard to see. Another treatment, **Aflibercept**, is already used for wAMD, and this study will compare the new treatments to it. **Neovascularization** is when new, unwanted blood vessels grow in the eye, and **macular degeneration** is when the part of the eye that gives you clear vision gets worse over time.

To join the study, you need to have a specific type of eye issue called **choroidal neovascularization (CNV)** and be new to treatment. The study checks if your vision is within a certain range using a test called **BCVA ETDRS**, which measures how many letters you can read on an eye chart. You also need to sign a form saying you understand the study.

• The study involves regular check-ups to monitor your eye condition.
• Participants must not have severe vision loss or large areas of damage in the study eye.
• Being part of the study means trying new treatments, which may have unknown risks.